5.95
+2.26(+61.25%)
Currency In USD
| Previous Close | 3.69 |
| Open | 3.67 |
| Day High | 6.42 |
| Day Low | 3.65 |
| 52-Week High | 6.42 |
| 52-Week Low | 1.61 |
| Volume | 80.03M |
| Average Volume | 1.2M |
| Market Cap | 509.26M |
| PE | -3.04 |
| EPS | -1.96 |
| Moving Average 50 Days | 3.51 |
| Moving Average 200 Days | 3.47 |
| Change | 2.26 |
If you invested $1000 in Larimar Therapeutics, Inc. (LRMR) 10 years ago, it would be worth $72.7 as of February 26, 2026 at a share price of $5.95. Whereas If you bought $1000 worth of Larimar Therapeutics, Inc. (LRMR) shares 5 years ago, it would be worth $348.56 as of February 26, 2026 at a share price of $5.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
GlobeNewswire Inc.
4 hours ago
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an u
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label studyFDA written communications after recent START meeting continue to alig
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
BALA CYNWYD, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’